source
- Pfizer secures two-year extension on Vyndamax patent, delaying competitionPfizer announced it has obtained an extension that pushes back the start of generic competition for its heart-failure drug Vyndamax (tafamidis) by about two years. Vyndamax ranks among Pfizer’s to…
- FDA commissioner touts real-time trial monitoring to cut drug development dead timeThe Food and Drug Administration announced a new approach that will let regulators view clinical trial endpoints as they happen, using cloud‑based data streams. The move targets the long delays th…